Tuesday, March 20, 2018

New cancer clinical trial: A Phase 1 Study of HLX10, a Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein in Patients With Advanced Solid Tumors

Published on: March 19, 2018 at 12:00PM
Condition:   Solid Tumor
Intervention:   Drug: HLX10
Sponsor:   Henlix, Inc
Recruiting
http://ift.tt/2u63jxY

No comments:

Post a Comment